Sensome Begins Human Trial for Its AI-Powered Stroke Guidewire
Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today that Gold Coast University Hospital (GCUH) in Australia enrolled the first patients in the Company’s CLOT OUT first-in-human study evaluating safety and performance of the Clotild® Smart Guidewire System in large-vessel acute ischemic stroke patients.
Acute ischemic stroke, a leading cause of long-term disability, can be treated by removing the clot blocking the brain blood vessel using mechanical thrombectomy devices, which are guided from the wrist or groin over a wire to the blockage. To improve patient prognosis, the clot needs to be removed as fast as possible. Today, without knowledge of the clot’s characteristics, the clot can only be removed on the first attempt in one out of three cases. Clotild® Smart Guidewire System integrating Sensome’s AI-powered tissue sensor enables the guidewire to provide physicians with critical information on the clot.
“Endovascular thrombectomy is no longer just about removing the clot. To get the best result for your patient, you need to get the clot out with complete revascularization the first time,” explains Dr Hal Rice, Director of Interventional Neuroradiology at GCUH, “The Clotild® guidewire is the first device that promises to provide live real time information during the intervention that can help increase our chances to choose the right interventional approach from the get-go.”
“Evidence has been mounting over the past few years that factors like the biological clot composition should be considered when choosing the fastest method to remove a clot,” indicates Dr Andrew Cheung, co-coordinating Investigator of the study with Dr Dennis Cordato, both at the Liverpool Hospital in New South Wales, Australia, “The CLOT OUT trial aims to demonstrate that using Clotild® in humans is safe and can detect clot composition.”
“After seven years of intense R&D we are now starting a new chapter,” emphasizes Franz Bozsak, CEO and co-founder of Sensome, “We are very excited to work with an exceptional team of investigators to achieve our goal of making a difference for large-vessel acute ischemic stroke patients.”
CLOT OUT is a multicenter, prospective trial intended to take place in leading stroke centers across Australia, Belgium and France and aims to enroll up to 100 patients. Data from the first cases will be presented at this year’s prestigious international LINNC Conference in Paris and interactive online stroke event SLICE Worldwide.
About Sensome
Sensome, a spin-off from CNRS and Ecole polytechnique (France), has developed a revolutionary sensor technology that turns invasive medical devices into connected healthcare devices. The company’s sensing technology combines impedance-based micro-sensors with machine learning algorithms to instantly identify biological tissues with unequaled predictive reliability. Its first application is the Clotild® connected guidewire for the treatment of ischemic stroke. Sensome's sensor technology can be deployed in multiple other medical fields, such as interventional cardiology and oncology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210912005010/en/
Contact information
For more information, please contact Franz Bozsak, press@sensome.com or +33 1 85 37 07 77
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabGenius Appoints Dr. Didier Landais as Chief Operating Officer22.9.2021 07:00:00 EEST | Press release
LabGenius, the machine learning (ML)-driven protein engineering company, has announced the appointment of Didier Landais Ph.D. as Chief Operating Officer. In this role, Didier will leverage his wealth of experience in business and clinical development to lead the commercialization of LabGenius’ drug discovery platform, EVA TM . This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005586/en/ LabGenius Appoints Dr. Didier Landais as Chief Operating Officer (Photo: Business Wire) “I’m delighted that Didier has joined the team,” said Dr. James Field, Founder and CEO of LabGenius. “Didier is a seasoned operator with 30 years of pharmaceutical industry experience and I’m looking forward to working with him as we rapidly grow the company. It’s a testament to the progress we have made at LabGenius and the exciting opportunities we have ahead of us that we were able to attract someone of Didier’s calibre to join us on our journey.” D
Mastercard Launches Strive: a Global Small Business Initiative to Accelerate Economic Recovery22.9.2021 06:20:00 EEST | Press release
Micro and small enterprises are important contributors to job creation and global economic development, representing approximately 90% of business and more than 50% of employment worldwide. However, the pandemic necessitated a rapid shift to digital platforms and processes that have created new opportunities but also pushed many to the brink of failure. To address the transition to digital, Mastercard - through the Center for Inclusive Growth - today launched Strive, a global initiative focused on strengthening the financial resilience of small businesses and supporting their recovery and growth. With an initial philanthropic investment of $25 million from the Mastercard Impact Fund, Strive will help more than five million micro and small businesses around the world access the tools and resources they need to digitize. “When small businesses thrive our local communities and economies thrive, but when they struggle, the impact is widespread,” said Michael Miebach, CEO of Mastercard. “Wh
Moody’s Announces Participation in New GFANZ Alliance: Commits to Align Products and Services to Achieve Net-Zero Greenhouse Gas Emissions by 205022.9.2021 02:01:00 EEST | Press release
Moody’s Corporation (NYSE: MCO) today announced its participation in launching the Net Zero Financial Services Provider Alliance as part of the Glasgow Financial Alliance for Net Zero (GFANZ). As a founding member, Moody’s commits to align all of its relevant products and services to achieve net-zero greenhouse gas emissions by 2050, in addition to reducing its own operational emissions. “Climate change is the world’s greatest risk multiplier and a profound challenge for economies and communities alike. The entire financial industry must take on the shared challenge of enabling an urgent shift to a resilient and sustainable economy. Aligning products and services with net-zero by 2050 will improve decision-making and accelerate the flow of capital to support the transition,” said Rob Fauber, President and Chief Executive Officer of Moody’s Corporation. “We are delighted to join the Net Zero Financial Services Provider Alliance as our latest step to empower organizations in making more
Former Irish Prime Minister Bertie Ahern Announces The World Carbon Neutrality Forum22.9.2021 02:01:00 EEST | Press release
The "World Carbon Neutrality Forum" (WCNF) was announced today by the former President of the European Council (2004) and former Irish Prime Minister Bertie Ahern. Mr Ahern is currently co-chair of the Interaction of Council of Former Heads of State and Government, and the Eco Global Forum. The date of 22nd September has been chosen to mark the first anniversary of President Xi’s double carbon commitment and his efforts towards a community with a shared future. The Forum is established to promote climate cooperation between China, the United States, Europe, and the rest of the World. In its first year of operation, the World Carbon Neutrality Forum will be held virtually and transmitted by a dedicated video platform called the World Carbon Neutrality Media Network. The Forum will be based on a Davos model and will seek to stimulate thoughts globally by leadership on decarbonisation. It is a pluralistic organisation which will meet each quarter and will invite current and former Heads o
Science, Innovation, and Inclusion Are Vital in Addressing the World’s Most Pressing Issues, Says PMI CEO in Speech at Concordia Summit21.9.2021 23:24:00 EEST | Press release
Jacek Olczak, Chief Executive Officer of Philip Morris International Inc. (PMI) (NYSE: PM), today delivered remarks at the 2021 Concordia Annual Summit. Olczak discussed the need to draw on the lessons learned from the global response to COVID-19 and create transparent frameworks and partnerships that harness innovation to build a better world. He explained the importance of focusing on peer-reviewed science to tackle major global issues—including environmental pressure, social inequality, health pandemic, and smoking. Olczak described how the exclusionary practices of many anti-tobacco organizations and NGOs are making it harder for PMI to deliver tobacco harm reduction solutions by introducing scientifically substantiated alternatives as the company moves away from making and selling cigarettes. The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster
‘Hidden Gem’ Arrives in Rotterdam to be Transformed into Nodule Collection Vessel for The Metals Company21.9.2021 19:37:00 EEST | Press release
The Metals Company (Nasdaq: TMC) today announced that the 228-meter-long former drill ship renamed the Hidden Gem has arrived in Rotterdam, The Netherlands to begin its conversion into what is expected to be the first ship classified as a sub-sea mining vessel by the American Bureau of Shipping. TMC’s strategic partner Allseas acquired the former ultra-deep-water drill ship, which can accommodate 200 people, in March of 2020, as her configuration is well-suited for modifications that will enable the deployment at sea of a 4.5 kilometer-long riser to bring polymetallic nodules up from the seafloor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005945/en/ Hidden Gem vessel (Photo: Business Wire) In partnership with The Metals Company (formerly DeepGreen Metals Inc.), Allseas is developing a deep-sea mineral collection system to responsibly recover polymetallic nodules from the ocean floor and transfer them to the surfac
Rhizen Pharmaceuticals AG Announces First Patient Dosed in a Phase 2 Study of RP7214 in Covid-19 Patients21.9.2021 19:36:00 EEST | Press release
Rhizen Pharmaceuticals AG, a clinical-stage oncology & inflammation-focussed biopharmaceutical company, today announced that the first patient has been dosed in a Phase 2 clinical trial of RP7214, a small molecule oral dihydroorotate dehydrogenase (DHODH) Inhibitor. The randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy & safety of oral RP7214, in covid-19 patients with mild, symptomatic disease with an underlying risk factor on the background of promising preclinical efficacy & phase 1 healthy volunteer safety. The study is being conducted in India across 12 centres in coordination with Rhizen’s India affiliate, Incozen Therapeutics Pvt ltd., and is designed to enrol up to 204 patients across both study arms. Viral replication involves a huge demand for building blocks and relies on nucleotides derived from host cells. DHODH is a rate-limiting enzyme in the pyrimidine biosynthesis pathway, inhibition of which leads to depletion of host nucleotide po
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom